New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 1, 2022 - The FDA approved Fresenius Kabi’s Stimufend (pegfilgrastim-fpgk), biosimilar to Amgen’s Neulasta® (pegfilgrastim).
Download PDF
Return to publications
